C. Roche-Lestienne

发表

Mutations in the ABL kinase domain pre-exist the onset of imatinib treatment.

Claude Preudhomme, C. Preudhomme, C. Roche-Lestienne, 2003, Seminars in hematology.

Genomic characterization of Imatinib resistance in CD34+ cell populations from chronic myeloid leukaemia patients.

B. Quesnel, C. Preudhomme, E. Lippert, 2011, Leukemia research.

Bone morphogenetic protein antagonist gene NOG is involved in myeloproliferative disease associated with myelofibrosis.

X. Leleu, J. Andrieux, P. Vandenberghe, 2007, Cancer genetics and cytogenetics.

BACH2 promotes indolent clinical presentation in Waldenström macroglobulinemia

B. Quesnel, E. Bertrand, C. Preudhomme, 2016, Oncotarget.

A. Afenjar, T. Roscioli, A. Verloes, 2018, neurogenetics.

Isolated isochromosomes i(X)(p10) and idic(X)(q13) are associated with myeloid malignancies and dysplastic features

V. Eclache, E. Chapiro, F. Nguyen‐Khac, 2019, American journal of hematology.

Changes in the dynamics of the excess mortality rate in chronic phase-chronic myeloid leukemia over 1990-2007: a population study.

C. Preudhomme, T. Facon, L. Remontet, 2011, Blood.

Familial myeloid malignancies with germline TET2 mutation

G. Huet, B. Quesnel, C. Preudhomme, 2019, Leukemia.

WAGR syndrome and congenital hypothyroidism in a child with a Mosaic 11p13 deletion

G. Tachdjian, J. Andrieux, C. Vincent‐Delorme, 2017, American journal of medical genetics. Part A.

Increased risk of adverse acute myeloid leukemia after anti-CD19-targeted immunotherapies in KMT2A-rearranged acute lymphoblastic leukemia: a case report and review of the literature

C. Preudhomme, C. Roumier, C. Roche-Lestienne, 2019, Leukemia & lymphoma.

Poor prognosis of chromosome 7 clonal aberrations in Philadelphia-negative metaphases and relevance of potential underlying myelodysplastic features in chronic myeloid leukemia

P. Cony-Makhoul, C. Preudhomme, I. Tigaud, 2018, Haematologica.

The Lymphoid Variant of Hypereosinophilic Syndrome

G. Salles, A. Baruchel, M. Copin, 2014, Medicine.

The t(2;12)(p12;p13), leading to the juxtaposition of the cyclin D2 CCND2 gene with the immunoglobulin kappa locus (IGK), defines a small subset of mantle cell lymphomas lacking cyclin D1 expression.

C. Roche-Lestienne, N. Duployez, L. Pascal, 2017 .

TRIT1 deficiency: Two novel patients with four novel variants.

L. Faivre, C. Thauvin-Robinet, F. Petit, 2022, European journal of medical genetics.

Mutation status and clinical outcome of 89 imatinib mesylate-resistant chronic myelogenous leukemia patients: a retrospective analysis from the French intergroup of CML (Fi(ϕ)-LMC GROUP)

J. Cayuela, C. Preudhomme, M. Tulliez, 2006, Leukemia.

Genome wide SNP array identified multiple mechanisms of genetic changes in Waldenstrom macroglobulinemia

B. Quesnel, E. Bertrand, C. Preudhomme, 2013, American journal of hematology.

High frequency of RUNX1 biallelic alteration in acute myeloid leukemia secondary to familial platelet disorder.

A. Baruchel, C. Preudhomme, H. Sobol, 2009, Blood.

Whole-genome optical mapping to elucidate myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase gene fusions.

C. Roche-Lestienne, N. Grardel, Augustin Boudry, 2022, Leukemia research.

Clinical outcome of 27 imatinib mesylate-resistant chronic myelogenous leukemia patients harboring a T315I BCR-ABL mutation

C. Preudhomme, M. Tulliez, S. Hayette, 2007, Haematologica.

Incidence and prognostic value of TET2 alterations in de novo acute myeloid leukemia achieving complete remission.

J. Soulier, J. Cayuela, H. Dombret, 2010, Blood.

Subclonal acquisition of a BCR::ABL1 fusion in a chronic myelomonocytic leukemia

C. Berthon, O. Nibourel, Laure Goursaud, 2022, Annals of Hematology.

Mutation analysis of TET2, IDH1, IDH2 and ASXL1 in chronic myeloid leukemia

C. Preudhomme, P. Rousselot, F. Mahon, 2011, Leukemia.

Neurofibromatosis‐1 gene deletions and mutations in de novo adult acute myeloid leukemia

J. Soulier, H. Dombret, C. Preudhomme, 2013, American journal of hematology.

Coexistence of AML1/RUNX1 and BCR-ABL point mutations in an imatinib-resistant form of CML

I. Yakoub-Agha, C. Preudhomme, T. Facon, 2005, Leukemia.

Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia: Recommendations for clinical practice from the French Chronic Myeloid Leukemia Study Group

J. Cayuela, P. Cony-Makhoul, P. Rousselot, 2018, Cancer.

The BCR-ABLT315I mutation compromises survival in chronic phase chronic myelogenous leukemia patients resistant to tyrosine kinase inhibitors, in a matched pair analysis

Martin C. Müller, I. Dufva, D. Marin, 2013, Haematologica.

The BCR-ABLT 315 I mutation compromises survival in chronic phase chronic myelogenous leukemia patients resistant to tyrosine kinase inhibitors , in a matched pair analysis

Martin C. Müller, I. Dufva, D. Marin, 2013 .

Mechanisms of genesis of variant translocation in chronic myeloid leukemia are not correlated with ABL1 or BCR deletion status or response to imatinib therapy.

V. Eclache, J. Andrieux, J. Laï, 2008, Cancer genetics and cytogenetics.

RUNX1 DNA-binding mutations and RUNX1-PRDM16 cryptic fusions in BCR-ABL+ leukemias are frequently associated with secondary trisomy 21 and may contribute to clonal evolution and imatinib resistance.

C. Preudhomme, I. Tigaud, J. Laï, 2007, Blood.

Randomized Comparison of Imatinib Versus Imatinib Combination Therapies in Newly Diagnosed Chronic Myeloid Leukaemia (CML) Patients in Chronic Phase (CP): First Results of the Phase III (SPIRIT) Trial from the French CML Group (FI LMC)

A. Vekhoff, C. Preudhomme, V. Eclache, 2008 .

GILZ inhibits the mTORC2/AKT pathway in BCR-ABL+ cells

B. Quesnel, C. Preudhomme, T. Idziorek, 2011, Oncogene.

Cryptic and partial deletions of PRDM16 and RUNX1 without t(1;21)(p36;q22) and/or RUNX1–PRDM16 fusion in a case of progressive chronic myeloid leukemia: A complex chromosomal rearrangement of underestimated frequency in disease progression?

C. Preudhomme, J. Laï, C. Roche-Lestienne, 2008, Genes, chromosomes & cancer.

Correction: Refinement of 1p36 Alterations Not Involving PRDM16 in Myeloid and Lymphoid Malignancies

F. Speleman, M. Vikkula, L. Michaux, 2011, PLoS ONE.

Germline PAX5 mutation predisposes to familial B acute lymphoblastic leukemia.

C. Preudhomme, Aurélie Caillault, C. Berthon, 2020, Blood.

Lessons from the analysis of TAD boundary deletions in normal population

F. Petit, C. Roche-Lestienne, T. Smol, 2020, bioRxiv.

Inhibiting the oncogenic translation program is an effective therapeutic strategy in multiple myeloma

J. Bradner, N. Gray, B. Quesnel, 2017, Science Translational Medicine.

The LIN28B/let-7 axis is a novel therapeutic pathway in Multiple Myeloma

John T. Powers, G. Daley, A. Roccaro, 2016, Leukemia.

Neurodevelopmental phenotype associated with CHD8-SUPT16H duplication

S. Bouquillon, C. Roche-Lestienne, A. Dieux-Coeslier, 2019, neurogenetics.

Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment.

Claude Preudhomme, Pierre Fenaux, C. Preudhomme, 2002, Blood.

NUP98 is rearranged in 3.8% of pediatric AML forming a clinical and molecular homogenous group with a poor prognosis

G. Leverger, I. Radford‐Weiss, I. Luquet, 2017, Leukemia.

A mutation conferring resistance to imatinib at the time of diagnosis of chronic myelogenous leukemia.

C. Preudhomme, T. Facon, J. Laï, 2003, The New England journal of medicine.

Targeting MYC in multiple myeloma

B. Quesnel, I. Ghobrial, T. Facon, 2017, Leukemia.

Molecular characterization of the idiopathic hypereosinophilic syndrome (HES) in 35 French patients with normal conventional cytogenetics

B. Quesnel, C. Preudhomme, P. Fenaux, 2005, Leukemia.

Low-dose imatinib mesylate leads to rapid induction of major molecular responses and achievement of complete molecular remission in FIP1L1-PDGFRA-positive chronic eosinophilic leukemia.

M. Rondoni, G. Martinelli, C. Preudhomme, 2007, Blood.

Sustained molecular response with imatinib in a leukemic form of idiopathic hypereosinophilic syndrome in relapse after allograft

C. Preudhomme, C. Rose, E. Bourgeois, 2004, Leukemia.

PRDM16 (1p36) translocations define a distinct entity of myeloid malignancies with poor prognosis but may also occur in lymphoid malignancies

F. Speleman, L. Michaux, E. Lippert, 2011, British journal of haematology.

The prognosis impact of BCR-ABL P-loop mutations: worse or not worse?

C. Preudhomme, F. Nicolini, Q. Le, 2007, Leukemia.

Acquisition of genomic events leading to lymphoblastic transformation in a rare case of myeloproliferative neoplasm with BCR–JAK2 fusion transcript

C. Preudhomme, C. Berthon, O. Nibourel, 2016, European journal of haematology.

Chronic myeloproliferative disorder with t(8;22)(p11;q11) can mime clonal cytogenetic evolution of authentic chronic myelogeneous leukemia

C. Preudhomme, Aline Renneville, J. Laï, 2008, Genes, chromosomes & cancer.

MYD88 L265P mutation in Waldenstrom macroglobulinemia.

B. Quesnel, E. Bertrand, C. Preudhomme, 2012, Blood.

Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia.

Claude Preudhomme, Philippe Rousselot, A. Vekhoff, 2010, The New England journal of medicine.

CD3−CD4+ lymphoid variant of hypereosinophilic syndrome: nodal and extranodal histopathological and immunophenotypic features of a peripheral indolent clonal T-cell lymphoproliferative disorder

G. Salles, M. Copin, C. Preudhomme, 2015, Haematologica.

Refinement of 1p36 Alterations Not Involving PRDM16 in Myeloid and Lymphoid Malignancies

F. Speleman, M. Vikkula, L. Michaux, 2011, PloS one.

Factors predicting molecular and cytogenetic response in chronic myeloid leukemia patients treated with imatinib.

C. Preudhomme, T. Facon, J. Laï, 2005, Haematologica.

Acute megakaryoblastic leukemia with der(7)t(5;7)(q11;p11∼p12) associated with Down syndrome: a fourth case report

J. Andrieux, N. Dastugue, J. Laï, 2006 .

Complex karyotype in mantle cell lymphoma is a strong prognostic factor for the time to treatment and overall survival, independent of the MCL international prognostic index

F. Jardin, H. Tilly, S. Chevret, 2014, Genes, chromosomes & cancer.

TP53 Mutation and Its Prognostic Significance in Waldenstrom's Macroglobulinemia

B. Quesnel, E. Bertrand, C. Preudhomme, 2017, Clinical Cancer Research.

Clinical Outcome of 27 Imatinib Mesylate Resistant Chronic Myelogenous Leukemia (CML) Patients Harbouring a T315I BCR-ABL Mutation.

C. Preudhomme, M. Tulliez, S. Hayette, 2006 .

Isolated tetrasomy 8 in AML, MDS and MPD

O. Nibourel, J. Laï, C. Roche-Lestienne, 2011 .

Detection of dicentric chromosome (9;20) in paediatric B-cell acute lymphoblastic leukaemia: prognostic significance

P. Schneider, J. Vannier, C. Roche-Lestienne, 2015, Annals of Hematology.

Disease escape with the selective loss of the Philadelphia chromosome after tyrosine kinase inhibitor exposure in Ph-positive acute lymphoblastic leukemia

B. Quesnel, C. Preudhomme, C. Berthon, 2020, Leukemia.

The molecular anatomy of the FIP1L1-PDGFRA fusion gene

R. Yeh, M. Baccarani, G. Martinelli, 2009, Leukemia.

Tetraspanin CD81 is an adverse prognostic marker in acute myeloid leukemia

B. Quesnel, A. Duhamel, C. Preudhomme, 2016, Oncotarget.

First Overall Molecular Response of the Randomized French SPIRIT Study on Behalf the Fi-LMC Group.

C. Preudhomme, F. Mahon, F. Guilhot, 2006 .

Diagnosis of intrachromosomal amplification of chromosome 21 (iAMP21) by molecular cytogenetics in pediatric acute lymphoblastic leukemia

C. Preudhomme, C. Roche-Lestienne, N. Grardel, 2015, Clinical case reports.

Association of TET2 Alterations with NPM1 Mutations and Prognostic Value in De Novo Acute Myeloid Leukemia (AML).

J. Soulier, J. Cayuela, H. Dombret, 2009 .

Classification of Hodgkin lymphoma over years

A. Carbone, A. Gloghini, C. Roche-Lestienne, 2018, Atlas of Genetics and Cytogenetics in Oncology and Haematology.

Cytogenetics in the management of "chronic myeloid leukemia": an update by the Groupe francophone de cytogénétique hématologique (GFCH).

M. Mozziconacci, C. Roche-Lestienne, E. Boudry-Labis, 2016, Annales de biologie clinique.

The Presence of the BCR-ABL T315I Mutation In Chronic Phase Chronic Myelogenous Leukemia Resistant to Tyrosine Kinase Inhibitors Profoundly Compromises Overall Survival and Progression Free Survival. Preliminary Results of a Matched Pair Analysis.

Martin C. Müller, I. Dufva, G. Martinelli, 2010 .

RUNX1 DNA-binding mutations and RUNX1-PRDM16 cryptic fusions in BCR-ABL+ leukemias are frequently associated with secondary trisomy 21 and may contribute to clonal evolution and imatinib resistance.

C. Preudhomme, I. Tigaud, J. Laï, 2007, Blood.

The BCR-ABLT315I mutation compromises survival in chronic phase chronic myelogenous leukemia patients resistant to tyrosine kinase inhibitors, in a matched pair analysis

Martin C. Müller, I. Dufva, D. Marin, 2013, Haematologica.

Mutation Status of Imatinib Mesylate-Resistants CML Patients and Clinical Outcomes: A French Multicenter Retrospective Study for the fiLMC Group.

C. Preudhomme, S. Hayette, G. Marit, 2004 .

Cytogenetics in the management of myeloproliferative neoplasms, mastocytosis and myelodysplastic/myeloproliferative neoplasms: Guidelines from the Group Francophone de Cytogénétique Hématologique (GFCH).

C. Roche-Lestienne, C. Godon, Emilie Klein, 2023, Current research in translational medicine.

TP53 Mutation and Its Prognostic Significance in Waldenstrom's Macroglobulinemia

B. Quesnel, E. Bertrand, C. Preudhomme, 2017, Clinical Cancer Research.

Genome wide SNP array identified multiple mechanisms of genetic changes in Waldenstrom macroglobulinemia

B. Quesnel, E. Bertrand, C. Preudhomme, 2013, American journal of hematology.